Viatris Charts New Course with Major Restructuring and Focus on Innovation

PITTSBURGH, PA – February 26, 2026 – Viatris Inc. (Nasdaq: VTRS) today announced a significant strategic pivot designed to streamline operations and fuel future growth, following a year of robust financial performance that saw the company meet or exceed all its 2025 guidance metrics. The global healthcare giant unveiled a comprehensive plan that includes delivering $650 million in cost savings, reinvesting up to $250 million in growth areas, and a global workforce reduction of up to 10% over the next three years.

The announcement came as Viatris reported total revenues of $3.7 billion for the fourth quarter and $14.3 billion for the full year 2025. The company signaled confidence in its new direction by issuing 2026 revenue guidance of $14.45 billion to $14.95 billion, a forecast that sits above current analyst consensus.

"2025 was a year of strong execution across our global business, and we enter 2026 from a position of strength," said CEO Scott A. Smith in a statement, calling the day an "important inflection point in Viatris' evolution." He added that the changes are intended to make Viatris a "more focused, efficient and future-ready organization."

A Strategic Overhaul for Future Growth

The centerpiece of the announcement is the completion of an enterprise-wide strategic review. This overhaul aims to optimize everything from commercial and R&D activities to the company's vast manufacturing and supply chain network. The resulting plan projects total cost savings of approximately $650 million, with about 30% of the net savings expected to be realized in 2026.

To achieve this, Viatris will undergo a significant restructuring, which includes a global workforce reduction of up to 10%. The company anticipates incurring pre-tax charges between $700 million and $850 million, primarily related to severance, contract terminations, and network modernization costs spread over the next three years.

Company leadership emphasized that these measures are not merely about cost-cutting but about strategic realignment. Viatris plans to reinvest up to $250 million of the savings into areas that will enhance its growth profile, including its innovation pipeline and commercial capabilities.

"In 2026, we anticipate continued operational growth driven by our base business and net cost savings," stated CFO Doretta Mistras. She noted the company expects to be in a "strong financial position with significant cash available for deployment to deliver on our balanced capital allocation framework."

Beyond Generics: A Pipeline Fueled by Innovation

While streamlining operations, Viatris is simultaneously making a clear push beyond its traditional generics foundation toward more innovative and high-margin therapies. The company's pipeline is a key component of this strategy, with regulatory decisions anticipated for six product candidates in 2026.

Among the most watched is MR-141, an ophthalmic solution for presbyopia, a common age-related eye condition affecting nearly 90% of U.S. adults over 45. The FDA has set a target action date of October 17, 2026, for a decision. Another key candidate is an investigational low-dose estrogen weekly contraceptive patch, with an FDA goal date of July 30, 2026.

Viatris is also advancing into cutting-edge therapeutic areas. In December, the FDA cleared its Investigational New Drug (IND) application for MR-146, a novel gene therapy candidate for neurotrophic keratopathy, a rare and potentially sight-threatening degenerative eye disease. The company is also expanding its global footprint with new products, having launched Inpefa, a dual SGLT1/2 inhibitor for heart failure, in the United Arab Emirates this past January.

This push into innovation is complemented by success in complex generics. The FDA recently approved Viatris's generic version of Sandostatin® LAR Depot, an injectable drug using sophisticated microsphere technology, underscoring the company's manufacturing expertise.

Navigating Headwinds and Managing Risk

The company's forward-looking strategy comes against a backdrop of successfully navigating operational and financial challenges. Viatris's full-year 2025 results included a U.S. GAAP net loss of $3.5 billion, largely driven by a previously disclosed non-cash goodwill impairment charge of $2.9 billion recorded earlier in the year.

More recently, Viatris has been managing a disruption in its global supply chain. In mid-February, a fire occurred at its oral solid dose manufacturing facility in Nashik, India, leading to a temporary suspension of manufacturing. The company stated that it has factored the shutdown into its 2026 financial guidance and expects to resume operations in April. The incident highlights the inherent vulnerabilities within the global pharmaceutical supply chain, which relies heavily on manufacturing hubs in countries like India.

Despite these headwinds, the company's ability to meet its 2025 financial commitments and provide optimistic guidance for 2026 suggests a high degree of operational resilience and proactive risk management.

Delivering Shareholder Value

For investors, Viatris is reinforcing its commitment to a "total return" strategy. The company returned over $1 billion to shareholders in 2025 through dividends and share repurchases. Its 2026 capital allocation plan continues this focus, with a commitment to maintain its annual dividend of $0.48 per share and continue share buybacks.

With over $2.5 billion in cash expected to be available for deployment in 2026, the company also plans to pursue strategic, in-market acquisitions to accelerate growth. This follows a multi-year program of divesting non-core assets that generated nearly $7 billion in proceeds, strengthening the balance sheet and sharpening the company's focus.

Viatris has scheduled an Investor Event for March 19, 2026, where executives are expected to provide a deeper look into the company's long-term outlook, R&D capabilities, and commercial strategy for its upcoming product launches.